Single-agent pegylated liposomal doxorubicin (PLD) in the treatment of metastatic breast cancer: results of an Austrian observational trial

@inproceedings{Fiegl2011SingleagentPL,
  title={Single-agent pegylated liposomal doxorubicin (PLD) in the treatment of metastatic breast cancer: results of an Austrian observational trial},
  author={Michael Fiegl and Brigitte Mlineritsch and M Hubalek and Rupert Bartsch and Ursula Pluschnig and Guenther G. Steger},
  booktitle={BMC Cancer},
  year={2011}
}
In advanced breast cancer, multiple sequential lines of treatments are frequently applied. Pegylated liposomal doxorubicin (PLD) has a favourable toxicity profile and can be used in first or higher lines of therapy. PLD has demonstrated response activity even after prior anthracycline exposure. 129 consecutive patients with advanced breast cancer, of whom the majority had been massively pretreated, received PLD as monotherapy within licensed approval, for which efficacy and toxicities were… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 12 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 28 references

Toxic effects occurring during treatment of advanced breast cancer with PLD (described in at least 2 PLD-treated patients) Toxic effects

  • S Beslija, J Bonneterre, +16 authors N Wilcken
  • Exanthema
  • 2011
1 Excerpt

Bevacizumab-based combination therapy in a patient with pseudomyxoma peritonei

  • WL Sun, G Hutarew, +4 authors M Fiegl
  • Memo
  • 2009

Similar Papers

Loading similar papers…